At what enterprise value was UNITHER acquired in 2017?

During the acquisition of UNITHER by ARDIAN in 2017, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of UNITHER when it was acquired by ARDIAN?

The exact EV/EBITDA multiple for UNITHER is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was UNITHER acquired by ARDIAN?

UNITHER was acquired by ARDIAN in 2017.

What was the revenue of UNITHER at the time of the deal?

The revenue of UNITHER at the time of the deal is estimated to be in the range of 250M - 500M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the UNITHER acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the UNITHER deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cfnews.net/L-actualite/LBO/Operations/LBO-Quaternaire/Unither-boucle-son-quatrieme-LBO-242441

← DATABASE

Home Database Healthcare & PharmaUNITHER

03/2017

UNITHER acquired by ARDIAN

FRANCE Life Sciences / Pharma & Biotech / CDMO EV 500M - 1.5b EUR

Context

Ardian, an independent private investment firm, has entered into exclusive negotiations to acquire a majority stake in Unither Pharmaceuticals, a global leader in the Contract Development and Manufacturing Organization (CDMO) sector. Ardian submitted a firm offer to Equistone, which leads a consortium of sellers including historical shareholders Parquest Capital and CM-CIC Investissement.

UNITHER, which reported an EBITDA margin of LOGIN in 2016, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Global leader in sterile unit-dose manufacturing using Blow-Fill-Seal (BFS) technology. The group provides contract development and manufacturing services for pharmaceutical companies, specializing in ophthalmology, respiratory diseases, and saline solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2016

2015

Other operations with UNITHER

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
10/2022	IK PARTNERS	UNITHER	FRANCE	Life Sciences	Unither Pharmaceuticals, a global leader in sterile single-unit dosage manufacturing, has undergone a capital reorganization led by its management team and a consortium of prominent investors. GIC and IK Partners have entered as new equity partners, while Keensight Capital and Parquest are reinvesting to reinforce their existing positions. The consortium is acquiring the majority stake from Ardian, following a successful five-year partnership.

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of UNITHER by ARDIAN are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Acquirer: ardian